Streetbeat News

Price Targets

UNH

Truist Securities analyst David Macdonald reiterates a Buy rating on UnitedHealth Group (UNH) with a maintained price target of $600.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:23 pm

SAGE

Wedbush analyst Laura Chico reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $24 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:21 pm

PGNY

Truist Securities analyst Jailendra Singh has reiterated a Buy rating on Progyny (NASDAQ:PGNY) and maintained a $46 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:21 pm

RARE

Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $48 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:21 pm

IP

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on International Paper (NYSE:IP) and maintained a $40 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:20 pm

EWTX

Truist Securities analyst Srikripa Devarakonda has reaffirmed a Buy rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:19 pm

NBIX

Wedbush analyst Laura Chico reiterates an Outperform rating on Neurocrine Biosciences (NBIX) and maintains a $147 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:19 pm

HD

Truist Securities analyst Scot Ciccarelli has maintained a Buy rating on Home Depot (HD) with a price target of $417.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:18 pm

ACN

Recent options market activity indicates a bearish sentiment towards Accenture (NYSE:ACN), with a notable volume of trades suggesting expectations for the stock's price to range between $310.0 and $330.0. Analysis of the largest trades reveals a mix of bullish, bearish, and neutral positions. Accenture, a global IT-services firm, has seen its stock price slightly decrease to $313.89. Analysts have varied opinions, with a consensus target price of $400.6, but recent adjustments include a downgrade by Mizuho to Buy with a target of $398.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 5:16 pm

JNJ

RBC Capital analyst Shagun Singh maintains an Outperform rating on Johnson & Johnson (JNJ) but lowers the price target from $181 to $175.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:11 pm